**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79951

**Manuscript Type:** OPINION REVIEW

**COVID-19 and liver injury in individuals with obesity**

Lempesis IG *et al*. COVID-19 liver injury in obesity

Ioannis G Lempesis, Eleni Karlafti, Petros Papalexis, George Fotakopoulos, Kyriakos Tarantinos, Vasileios Lekakis, Stavros P Papadakos, Evangelos Cholongitas, Vasiliki E Georgakopoulou

**Ioannis G Lempesis,** Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, United Kingdom

**Ioannis G Lempesis,** Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht 616 6200, Netherlands

**Eleni Karlafti,** Department of Emergency, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki 546 21, Greece

**Petros Papalexis,** Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece

**Petros Papalexis,** Department of Biomedical Sciences, University of West Attica, Athens 12243, Greece

**George Fotakopoulos,** Department of Neurosurgery, General University Hospital of Larisa, Larisa 41221, Greece

**Kyriakos Tarantinos,** First Pulmonology Department, Sismanogleio Hospital, Athens 15126, Greece

**Vasileios Lekakis, Stavros P Papadakos,** Department of Gastroenterology, Laiko General Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece

**Evangelos Cholongitas,** First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece

**Vasiliki E Georgakopoulou,** Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital, Athens 11527, Greece

**Author contributions:** Karlafti E and Tarantinos K designed the research; Fotakopoulos G, Papalexis P, Lekakis V and Papadakos SP performed the research; Lempesis IG wrote the article; Cholongitas E and Georgakopoulou VE revised the article.

**Corresponding author: Vasiliki E Georgakopoulou, Doctor, MSc, Academic Research, Doctor,** Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital, 17 Agiou Thoma Street, Athens 11527, Greece. vaso\_georgakopoulou@hotmail.com

**Received:** September 12, 2022

**Revised:** December 18, 2022

**Accepted:** January 9, 2023

**Published online:**February 14, 2023

**Abstract**

Coronavirus disease 2019 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 that manifests as a variety of clinical manifestations, including liver damage commonly detected by a hepatocellular pattern from liver function tests. Liver injury is associated with a worse prognosis overall. Conditions associated with the severity of the disease include obesity and cardiometabolic comorbidities, which are also associated with nonalcoholic fatty liver disease (NAFLD). The presence of NAFLD, similarly to obesity, is associated with an unfavourable impact on the coronavirus disease 2019 outcome. Individuals with these conditions could present with liver damage and elevated liver function tests due to direct viral cytotoxicity, systemic inflammation, ischemic or hypoxic liver damage or drug side effects. However, liver damage in the setting of NAFLD could also be attributed to a pre-existing chronic low-grade inflammation associated with surplus and dysfunctional adipose tissue in these individuals. Here we investigate the hypothesis that a pre-existing inflammatory status is exacerbated after severe acute respiratory syndrome coronavirus 2 infection, which embodies a second hit to the underestimated liver damage.

**Key Words:** COVID-19; SARS-CoV-2; Non-alcoholic fatty liver disease; Obesity; Inflammation; Liver; Adipose tissue

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lempesis IG, Karlafti E, Papalexis P, Fotakopoulos G, Tarantinos K, Lekakis V, Papadakos SP, Cholongitas E, Georgakopoulou VE. COVID-19 and liver injury in individuals with obesity. *World J Gastroenterol* 2023; 29(6): 908-916

**URL:** <https://www.wjgnet.com/1007-9327/full/v29/i6/908.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v29.i6.908

**Core Tip:** The severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 has a variety of clinical manifestations, including liver damage. Obesity and other dysmetabolic diseases linked to nonalcoholic fatty liver disease are a few of the factors that contribute to the severity of the illness. Due to direct viral cytotoxicity, people with these illnesses may have liver damage and increased liver function tests. However, liver injury might also be related to pre-existing inflammation and the detrimental effects of excessive and dysfunctional adipose tissue in these people.

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1,2], which was first identified in December 2019 in Wuhan, China, and has since spread globally, resulting in an ongoing pandemic[2]. COVID-19 represents a systemic disease that can cause a variety of clinical manifestations, which range from asymptomatic individuals to mild respiratory symptoms and severe critical illness[3-7]. A plethora of underlying pathways drive the pathophysiology, including activation or dysregulation of localized (*e.g.,* vascular) and generalized inflammation, which leads to multiorgan failure and eventually death[,8-12].

Among the clinical manifestations, liver involvement, indicated by abnormal liver function tests (LFT) in patients, was noted early in the pandemic’s development[13]. However, major liver damage is not common[14-18]. The liver may be affected by SARS-CoV-2 directly (*i.e.* translocation of the virus from the intestines to the liver) or *via* indirect ways (*i.e.* systemic inflammatory response, ischemic and hypoxic liver damage, drug-related liver injury and impacts on pre-existing liver diseases)[14,16,17]. Coexisting liver disease, including metabolic/obesity related nonalcoholic fatty liver disease (NAFLD), may also negatively impact the course of COVID-19[14,15].

Early observations of COVID-19 have highlighted obesity as one of the most common underlying conditions in patients hospitalized with COVID-19[19-21]. Obesity was further associated with hospital admission and as an independent predictor of severity, intensive medical intervention and mortality of COVID-19[15,19]. Obesity, determined by increased total fat mass (body mass index > 30 kg/m2), is a chronic multifactorial disease that predisposes patients to numerous comorbidities, including metabolic diseases (insulin resistance states, type 2 diabetes mellitus, NAFLD), cardiovascular diseases[15,22-24] and various types of cancer[25-28].

 Patients with poorer clinical outcomes for COVID-19 are characteristically older (more than 60 years) and have several metabolic syndrome manifestations, obesity and type 2 diabetes mellitus, a profile similar to those at increased risk of NAFLD[13,29,30]. Coexisting hepatic diseases like NAFLD and metabolic dysregulations could theoretically impact the manifestations and progression of COVID-19, and the liver injury in that population could represent a combination of the underlying condition exacerbated by the virus and inflammatory responses.

Here, we presented the current evidence for hepatic involvement in COVID-19 in obese individuals and the impact of fatty liver disease. Then, we tested the idea that liver damage in people with obesity and/or NAFLD could be caused by a “second hit” from the virus on top of hepatic dysfunction that was already there. This is likely caused by metabolic dysregulation and a chronic inflammatory state that is linked to obesity.

**CURRENT EVIDENCE OF HEPATIC INVOLVEMENT IN COVID-19**

Patients with COVID-19 have experienced varying degrees of liver damage, ranging from self-limited hepatitis to significant liver injury and liver failure[31,32]. Impaired LFT without other hepatic manifestations was shown to be present in almost 50% of patients with COVID-19 in various studies[31-33]. The spectrum of pathological LFT includes elevated liver enzyme concentrations of transaminases [aspartate transaminase (AST), alanine transaminase (ALT)], cholestatic enzymes including alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), lactate dehydrogenase and bilirubin and impaired synthetic activity as seen with prothrombin time (PT) prolongation and decreased albumin concentrations**[**31,34]. Based on the pattern of the affected LFT, liver damage is categorized as parenchymal (AST, ALT), cholestatic (ALP, GGT) or mixed. The most common type of liver damage, in up to 75% of cases, is parenchymal, indicating hepatocellular damage as a major part of physiopathology[31,34,35].

Several studies have shown elevated AST or ALT during acute COVID-19 illness[36-39]. A higher proportion of patients with severe cases (46.2% *vs* 12.7% in mild cases) had elevated AST and ALT[36,40-42]. AST appeared to be elevated first, followed by ALT in patients with severe disease[33,34]. Accordingly, AST was found to be correlated with mortality and liver dysfunction[5], showing an increased odds ratio in severe cases in other studies[42,43]. Elevated LFT was also recorded in subclinical cases (AST in 8.7% and ALT in 8.9%)[39].

The cholestatic pattern of elevated LFT was typically accompanied by elevated parenchymal enzymes[31]. In both mild and severe cases, ALP and bilirubin levels were found to be moderately elevated[37]. In a systematic review and meta-analysis of 64 studies, it was shown that the prevalence of elevated total bilirubin (9.7%), GGT (15.0%) and ALP (4.0%) were lower compared to elevated levels of aminotransferases (AST 23.2% and ALT 21.1%)[44]. Interestingly, in a retrospective study where ALP and GGT concentration levels were usually within normal values, pathological levels of GGT were found in 37.6% of patients with NAFLD[45].

In addition, a meta-analysis of 24 studies showed that a significantly longer PT in patients with severe COVID-19 was associated with higher morbidity rates. Elshazli *et al*[46] also concluded in their systematic review that prolonged PT was associated with a higher risk of disease progression to severe COVID-19 and admission to an intensive care unit. Impaired synthetic liver function, as assessed by hypoalbuminemia, was present and associated with an increased risk in patients with COVID-19[47]. Similarly, hypoalbuminemia was correlated with the severity of the disease and morbidity[31].

Overall, irrespectively of which LFT was affected, once hepatic damage was involved, patients had an increased risk of mortality and severe disease, which was shown in a systematic review of 107 studies and 20874 patients[48]. Acute liver injury is an important predictor for disease development[49]. In patients with chronic liver disease, including NAFLD, liver damage may occur more often. Chronic liver disease from any cause was discovered to be a risk factor for extended hospitalization and the fatal course of COVID-19[31].

**FATTY LIVER DISEASE AND COVID-19**

The occurrence of NAFLD in patients with SARS-CoV-2 infection is substantial[4,31,50]. This is the case as specific cardiometabolic chronic conditions intrinsically linked to NAFLD (hypertension, diabetes, obesity, coronary artery disease, and cerebrovascular disease) have been noted as important risk factors associated with an increased risk of severe COVID-19[4,45,51]. In a recent meta-analysis and systematic review of 16 studies, Hayat *et al*[29] examined NAFLD prevalence, COVID-19 and the outcomes among patients with NAFLD *vs* those without. The study findings showed that individuals with NAFLD, as compared to those without, had a higher probability of severe COVID-19 and intensive care unit admission[29]. Furthermore, NAFLD patients tended to have higher COVID-19-related mortality compared to non-NAFLD patients[6,29].

Assessment of LFT and clinical outcomes in patients with or without NAFLD showed that in the vast majority of patients, liver damage was minor and hepatocellular in type[13,45]. A higher probability of abnormal LFT from admission to discharge was recorded for patients with NAFLD[13,45]. A Chinese analysis found that patients with NAFLD had a higher incidence of severe COVID-19 than those who did not have NAFLD but only those under 60-years-old. This observation was observed even after adjusting for potentially confounding factors like obesity, diabetes and hypertension[13,52]. In contrast to that age group, there was no association between patients age 60 years and older and NAFLD and the severity of COVID-19[13,52]. It was suggested that NAFLD-induced hepatic and systemic immune responses may worsen the severity of the cytokine storm in COVID-19 patients who are younger. Aside from that, older people often have other cardiometabolic comorbidities, which may change any link to NAFLD[13,52].

**NAFLD AND OBESITY**

Dysfunctional adipose tissue (AT), an organ critical for whole-body homeostasis, is a hallmark of obesity and obesity-related chronic cardiometabolic diseases[28,53-55]. Dysfunctional AT is distinguished by, among other things, hormonal/adipocytokine dysregulation, a state of chronic low-grade inflammation associated with adipocyte hypertrophy and lipid metabolism impairments (reduced capacity to buffer the daily influx of dietary lipids), resulting in ectopic fat accumulation[28,56-58]. Additionally, decreased AT blood flow, mitochondrial dysfunction and altered oxygenation are frequently present in obesity[28,59].

Several proinflammatory molecules are increased in obesity and are related to aspects of the metabolic syndrome and other metabolic dysfunctions, including tumour necrosis factor alpha, interleukin 6 (IL-6), plasminogen activator inhibitor-1, dipeptidyl peptidase 4 and monocyte chemoattractant protein-1[53,54,60-62]. IL-6 can activate macrophages and contribute to the cytokine storm seen in COVID-19[13,63]. The loss of muscle mass and its anti-inflammatory properties, which are common in sarcopenic obesity, may have a negative impact on the chronic inflammatory status, various comorbidities and COVID-19 outcomes[64].

Liver dysfunction associated with obesity and metabolic diseases, including the spectrum of NAFLD, is characterized by a multifactorial pathophysiological mechanism still under investigation involving multiple pathways[65]. It has been suggested that, in part, the inability to sufficiently increase subcutaneous AT triglyceride stores in response to excessive energy intake and weight gain causes lipids to be diverted to other organs, such as the liver and skeletal muscle, where they accumulate ectopically and cause cellular lipotoxicity. This results in insulin resistance and inflammation in these tissues[66-70].

**COVID-19: AN ADDITIONAL CAUSE OF LIVER DAMAGE IN PRE-EXISTING NAFLD AND OBESITY?**

The COVID-19 systemic inflammatory state is linked with the angiotensin converting enzyme 2 (ACE2) receptor expressed in a variety of tissues[2,9,11]. Many organ systems, including the lungs, liver, heart, kidney and blood vessels, contain ACE2 receptors[31]. AT of patients with obesity is estimated to exhibit higher amounts of ACE2, perhaps acting as a SARS-CoV-2 reservoir with delayed viral shedding time[13,63]. The structural spike protein, characteristic of SARS-CoV-2, predominantly promotes the host’s immunological reaction[9]. The spike protein attaches to ACE2 receptor sites on the cell membrane, facilitating cell penetration[9].

In the liver, ACE2 receptor expression is significantly higher in cholangiocytes than in hepatocytes[31,41]. Direct virus cytopathogenic effects, inflammatory responses and intrahepatic immune cell stimulation, (micro)vascular thrombosis, hepatic obstruction, destabilized gut-liver axis, drug-induced toxicity and interfacesall play a part in liver damage during COVID-19 infection[31,35,71]. Interestingly, as demonstrated in a diet-induced nonalcoholic steatohepatitis (NASH) model in rodents, ACE2 hepatic expression was shown to be dramatically elevated, potentially enhancing hepatic vulnerability towards SARS-CoV-2 infection in individuals with NAFLD and/or NASH[13,72]. However, the link between NAFLD and liver-induced production of SARS-CoV-2 vital entry proteins, essentially ACE2, is still debatable[13]. A direct viral cytotoxic effect on hepatocytes appeared to induce mitochondrial and endoplasmic reticulum damage (swelling and distention accordingly), decreased glycogen granules and malfunction of the cell membrane in hepatocytes[31,33,34,42]. As in dysmetabolic conditions, the homeostasis of the liver and metabolic parameters are already impaired. This could have an additional effect on NAFLD. Finally, moderate microvesicular steatosis, along with other histopathological findings in deceased COVID-19 patients, may indicate additional pathways of metabolic derangement and liver damage[73].

In addition, the hyperinflammatory status in COVID-19 may act as a “second hit” to an inflamed fatty liver, causing “acute-on-chronic” steatohepatitis with increased aminotransferases[13,74]. **I**mmune-mediated liver injury is caused by proinflammatory cytokines, chemokines and inflammatory cells produced against the SARS-CoV-2, which are also increased in obesity (IL-6, tumour necrosis factor)[32,34,75]. This may explain the finding that the C-reactive protein to albumin ratio was an independent risk factor for mortality in NAFLD patients with COVID-19 in one study[6]. Another significant immunological mediator of damage is viral-induced T cells (CD8)[31,32].

Another major cause of liver injury in COVID-19 appears to be coagulation disruption and endothelial damage[31,73].Obesity is associated with hypercoagulation/thrombotic status dysregulation due to increased circulating concentrations of factor VII, von Willebrand factor and fibrinogen[13]*.* Ischemia-induced hypoxic liver injury most likely promotes the establishment of microvascular thrombosis[13,63]. Hypoxia caused by pneumonia is another major cause of liver damage[31]. This could be made worse in the case of COVID-19 and obesity, which is linked to obstructive sleep apnea and lower oxygen levels[28].

Ultimately, other factors may contribute to liver damage. It could be the end result of antivirals, anti-inflammatory medications, anticoagulants, antibiotics and other treatments used to treat underlying cardiometabolic chronic conditions and utilized during the COVID-19 infection, leading to liver injury[31]. Finally, dysbiosis and gut microbiota changes that usually occur in obesity could be exacerbated during COVID-19 and due to various medications[31,76]. A summary of the mechanisms can be found in Figure 1.

**FUTURE PERSPECTIVES**

Future studies should focus on elucidating and comparing a variety of populations with various body mass indexes (including normal weight, overweight and various degrees of obesity) because to date few studies have examined the presence of liver steatosis in patients with overweight or obesity[77]. Furthermore, the extent of underlying liver damage (NASH, liver fibrosis, or even liver cancer) should be determined in people who have pre-existing NAFLD and to monitor the severity of the COVID-19 infection outcomes. Finally, it would be of great interest to examine the potential differential impact of COVID-19 infection due to different viral variants on individuals with NAFLD and other liver manifestations, as these studies are sparse and focus on cirrhosis of various aetiologies[78].

**CONCLUSION**

In conclusion, the poor clinical outcomes of COVID-19 and the greater risk of pathological LFTs seen in people with obesity and/or NAFLD are likely caused by immune activation and a tendency toward a proinflammatory state during obesity as well as by metabolic and immune-mediated parameters that place the liver at risk. Thus, obesity should be prevented, especially in the context of the COVID-19 pandemic.

**REFERENCES**

1 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

2 **Georgakopoulou VE**, Makrodimitri S, Triantafyllou M, Samara S, Voutsinas PM, Anastasopoulou A, Papageorgiou CV, Spandidos DA, Gkoufa A, Papalexis P, Xenou E, Chelidonis G, Sklapani P, Trakas N, Sipsas NV. Immature granulocytes: Innovative biomarker for SARS‑CoV‑2 infection. *Mol Med Rep* 2022; **26** [PMID: 35551416 DOI: 10.3892/mmr.2022.12733]

3 **Yue H**, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. *Ann Palliat Med* 2020; **9**: 1404-1412 [PMID: 32692208 DOI: 10.21037/apm-20-887]

4 **Gracia-Ramos AE**, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. *World J Gastroenterol* 2021; **27**: 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951]

5 **Cholongitas E**, Bali T, Georgakopoulou VE, Giannakodimos A, Gyftopoulos A, Georgilaki V, Gerogiannis D, Basoulis D, Eliadi I, Karamanakos G, Mimidis K, Sipsas NV, Samarkos M. Prevalence of abnormal liver biochemistry and its impact on COVID-19 patients' outcomes: a single-center Greek study. *Ann Gastroenterol* 2022; **35**: 290-296 [PMID: 35599935 DOI: 10.20524/aog.2022.0709]

6 **Cholongitas E**, Bali T, Georgakopoulou VE, Kamiliou A, Vergos I, Makrodimitri S, Samara S, Triantafylou M, Basoulis D, Eliadi I, Karamanakos G, Sipsas NV, Samarkos M. Comparison of liver function test- and inflammation-based prognostic scores for coronavirus disease 2019: a single center study. *Eur J Gastroenterol Hepatol* 2022; **34**: 1165-1171 [PMID: 36170686 DOI: 10.1097/MEG.0000000000002446]

7 **Georgakopoulou VE**, Bali T, Adamantou M, Asimakopoulou S, Makrodimitri S, Samara S, Triantafyllou M, Voutsinas PM, Eliadi I, Karamanakos G, Basoulis D, Chatzipanagiotou O, Adamopoulou E, Alevizou A, Athanasiadis M, Spandidos DA, Papalexis P, Tarantinos K, Sipsas NV, Samarkos M, Cholongitas E. Acute hepatitis and liver injury in hospitalized patients with COVID‑19 infection. *Exp Ther Med* 2022; **24**: 691 [PMID: 36277149 DOI: 10.3892/etm.2022.11627]

8 **Gkoufa A**, Maneta E, Ntoumas GN, Georgakopoulou VE, Mantelou A, Kokkoris S, Routsi C. Elderly adults with COVID-19 admitted to intensive care unit: A narrative review. *World J Crit Care Med* 2021; **10**: 278-289 [PMID: 34616662 DOI: 10.5492/wjccm.v10.i5.278]

9 **Georgakopoulou VE**, Gkoufa A, Garmpis N, Makrodimitri S, Papageorgiou CV, Barlampa D, Garmpi A, Chiapoutakis S, Sklapani P, Trakas N, Damaskos C. COVID-19 and Acute Pancreatitis: A Systematic Review of Case Reports and Case Series. *Ann Saudi Med* 2022; **42**: 276-287 [PMID: 35933608 DOI: 10.5144/0256-4947.2022.276]

10 **Georgakopoulou VE**, Gkoufa A, Damaskos C, Papalexis P, Pierrakou A, Makrodimitri S, Sypsa G, Apostolou A, Asimakopoulou S, Chlapoutakis S, Sklapani P, Trakas N, Spandidos DA. COVID-19-associated acute appendicitis in adults. A report of five cases and a review of the literature. *Exp Ther Med* 2022; **24**: 482 [PMID: 35761802 DOI: 10.3892/etm.2022.11409]

11 **Georgakopoulou VE**, Lembessis P, Skarlis C, Gkoufa A, Sipsas NV, Mavragani CP. Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes. *Front Med (Lausanne)* 2022; **9**: 850472 [PMID: 35372456 DOI: 10.3389/fmed.2022.850472]

12 **Madjid M**, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. *JAMA Cardiol* 2020; **5**: 831-840 [PMID: 32219363 DOI: 10.1001/jamacardio.2020.1286]

13 **Herta T**, Berg T. COVID-19 and the liver - Lessons learned. *Liver Int* 2021; **41** Suppl 1: 1-8 [PMID: 34155789 DOI: 10.1111/liv.14854]

14 **Méndez-Sánchez N**, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, Eslam M, Abenavoli L, Xie W, Teschke R, Carrion AF, Keaveny AP. What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. *J Clin Transl Hepatol* 2020; **8**: 0024 [PMID: 32309152 DOI: 10.14218/JCTH.2020.00024]

15 **Cordeiro A**, Ribamar A, Ramalho A. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. *Clin Res Hepatol Gastroenterol* 2022; **46**: 101807 [PMID: 34543756 DOI: 10.1016/j.clinre.2021.101807]

16 **Li J**, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. *J Clin Transl Hepatol* 2020; **8**: 13-17 [PMID: 32274341 DOI: 10.14218/JCTH.2020.00019]

17 **Portincasa P**, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. *Eur J Clin Invest* 2020; **50**: e13338 [PMID: 32589264 DOI: 10.1111/eci.13338]

18 **Bangash MN**, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol* 2020; **5**: 529-530 [PMID: 32203680 DOI: 10.1016/S2468-1253(20)30084-4]

19 **Hu X**, Pan X, Zhou W, Gu X, Shen F, Yang B, Hu Z. Clinical epidemiological analyses of overweight/obesity and abnormal liver function contributing to prolonged hospitalization in patients infected with COVID-19. *Int J Obes (Lond)* 2020; **44**: 1784-1789 [PMID: 32572128 DOI: 10.1038/s41366-020-0634-3]

20 **Garg S**, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C, George A, Budd A, Brammer L, Langley G, Hall AJ, Fry A. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 458-464 [PMID: 32298251 DOI: 10.15585/mmwr.mm6915e3]

21 **Zheng Y**, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018; **14**: 88-98 [PMID: 29219149 DOI: 10.1038/nrendo.2017.151]

22 **Heymsfield SB**, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. *N Engl J Med* 2017; **376**: 254-266 [PMID: 28099824 DOI: 10.1056/NEJMra1514009]

23 **Bray GA**, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The Science of Obesity Management: An Endocrine Society Scientific Statement. *Endocr Rev* 2018; **39**: 79-132 [PMID: 29518206 DOI: 10.1210/er.2017-00253]

24 **Renehan AG**, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008; **371**: 569-578 [PMID: 18280327 DOI: 10.1016/S0140-6736(08)60269-X]

25 **Martin SD**, McGee SL. Metabolic reprogramming in type 2 diabetes and the development of breast cancer. *J Endocrinol* 2018; **237**: R35-R46 [PMID: 29487204 DOI: 10.1530/JOE-18-0037]

26 **Renehan AG**, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. *Nat Rev Cancer* 2015; **15**: 484-498 [PMID: 26205341 DOI: 10.1038/nrc3967]

27 **Frühbeck G**, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, Halford JGC, Farpour-Lambert NJ, Blaak EE, Woodward E, Toplak H. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. *Obes Facts* 2019; **12**: 131-136 [PMID: 30844811 DOI: 10.1159/000497124]

28 **Lempesis IG**, van Meijel RLJ, Manolopoulos KN, Goossens GH. Oxygenation of adipose tissue: A human perspective. *Acta Physiol (Oxf)* 2020; **228**: e13298 [PMID: 31077538 DOI: 10.1111/apha.13298]

29 **Hayat U**, Ashfaq MZ, Johnson L, Ford R, Wuthnow C, Kadado K, El Jurdi K, Okut H, Kilgore WR, Assi M, Siddiqui AA. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis. *Kans J Med* 2022; **15**: 241-246 [PMID: 35899064 DOI: 10.17161/kjm.vol15.16522]

30 **Williamson EJ**, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**: 430-436 [PMID: 32640463 DOI: 10.1038/s41586-020-2521-4]

31 **Ozkurt Z**, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. *World J Clin Cases* 2022; **10**: 1140-1163 [PMID: 35211548 DOI: 10.12998/wjcc.v10.i4.1140]

32 **Cichoż-Lach H**, Michalak A. Liver injury in the era of COVID-19. *World J Gastroenterol* 2021; **27**: 377-390 [PMID: 33584070 DOI: 10.3748/wjg.v27.i5.377]

33 **Metawea MI**, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. *Dig Liver Dis* 2021; **53**: 146-152 [PMID: 32988758 DOI: 10.1016/j.dld.2020.09.010]

34 **Garrido I**, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. *Aliment Pharmacol Ther* 2020; **52**: 267-275 [PMID: 32402090 DOI: 10.1111/apt.15813]

35 **Boettler T**, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. *JHEP Rep* 2020; **2**: 100169 [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169]

36 **Wang Q**, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Xiong HF, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. *Mil Med Res* 2020; **7**: 28 [PMID: 32507110 DOI: 10.1186/s40779-020-00256-6]

37 **Lei F**, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; **72**: 389-398 [PMID: 32359177 DOI: 10.1002/hep.31301]

38 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]

39 **Shi H**, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; **20**: 425-434 [PMID: 32105637 DOI: 10.1016/S1473-3099(20)30086-4]

40 **Mao R**, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 667-678 [PMID: 32405603 DOI: 10.1016/S2468-1253(20)30126-6]

41 **Yao N**, Wang SN, Lian JQ, Sun YT, Zhang GF, Kang WZ, Kang W. [Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**: 234-239 [PMID: 32153170 DOI: 10.3760/cma.j.cn501113-20200226-00070]

42 **Wang Y**, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569-1578 [PMID: 32423584 DOI: 10.1016/S0140-6736(20)31022-9]

43 **Wu ZH**, Yang DL. A meta-analysis of the impact of COVID-19 on liver dysfunction. *Eur J Med Res* 2020; **25**: 54 [PMID: 33148326 DOI: 10.1186/s40001-020-00454-x]

44 **Wijarnpreecha K**, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D. COVID-19 and liver injury: a meta-analysis. *Eur J Gastroenterol Hepatol* 2021; **33**: 990-995 [PMID: 32639420 DOI: 10.1097/MEG.0000000000001817]

45 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044]

46 **Elshazli RM**, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin MN, Hussein MH, Killackey MT, Fawzy MS, Kandil E. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. *PLoS One* 2020; **15**: e0238160 [PMID: 32822430 DOI: 10.1371/journal.pone.0238160]

47 **Wong YJ**, Tan M, Zheng Q, Li JW, Kumar R, Fock KM, Teo EK, Ang TL. A systematic review and meta-analysis of the COVID-19 associated liver injury. *Ann Hepatol* 2020; **19**: 627-634 [PMID: 32882393 DOI: 10.1016/j.aohep.2020.08.064]

48 **Kulkarni AV**, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther* 2020; **52**: 584-599 [PMID: 32638436 DOI: 10.1111/apt.15916]

49 **Figliozzi S**, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, Stamatelopoulos K, Dimopoulos MA, Caforio ALP, Georgiopoulos G. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest* 2020; **50**: e13362 [PMID: 32726868 DOI: 10.1111/eci.13362]

50 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

51 **Petrilli CM**, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; **369**: m1966 [PMID: 32444366 DOI: 10.1136/bmj.m1966]

52 **Zhou YJ**, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. *J Hepatol* 2020; **73**: 719-721 [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027]

53 **Goossens GH**. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. *Physiol Behav* 2008; **94**: 206-218 [PMID: 18037457 DOI: 10.1016/j.physbeh.2007.10.010]

54 **Rosen ED**, Spiegelman BM. What we talk about when we talk about fat. *Cell* 2014; **156**: 20-44 [PMID: 24439368 DOI: 10.1016/j.cell.2013.12.012]

55 **Blüher M**. Adipose tissue dysfunction contributes to obesity related metabolic diseases. *Best Pract Res Clin Endocrinol Metab* 2013; **27**: 163-177 [PMID: 23731879 DOI: 10.1016/j.beem.2013.02.005]

56 **Shulman GI**. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med* 2014; **371**: 2237-2238 [PMID: 25470706 DOI: 10.1056/NEJMc1412427]

57 **Goossens GH**, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? *Front Endocrinol (Lausanne)* 2015; **6**: 55 [PMID: 25964776 DOI: 10.3389/fendo.2015.00055]

58 **Frayn KN**, Karpe F. Regulation of human subcutaneous adipose tissue blood flow. *Int J Obes (Lond)* 2014; **38**: 1019-1026 [PMID: 24166067 DOI: 10.1038/ijo.2013.200]

59 **Lempesis IG**, Goossens GH, Manolopoulos KN. Measurement of human abdominal and femoral intravascular adipose tissue blood flow using percutaneous Doppler ultrasound. *Adipocyte* 2021; **10**: 119-123 [PMID: 33591224 DOI: 10.1080/21623945.2021.1888471]

60 **Fasshauer M**, Blüher M. Adipokines in health and disease. *Trends Pharmacol Sci* 2015; **36**: 461-470 [PMID: 26022934 DOI: 10.1016/j.tips.2015.04.014]

61 **Lamers D**, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Müller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. *Diabetes* 2011; **60**: 1917-1925 [PMID: 21593202 DOI: 10.2337/db10-1707]

62 **Kim CS**, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. *Int J Obes (Lond)* 2006; **30**: 1347-1355 [PMID: 16534530 DOI: 10.1038/sj.ijo.0803259]

63 **Pasquarelli-do-Nascimento G**, Braz-de-Melo HA, Faria SS, Santos IO, Kobinger GP, Magalhães KG. Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. *Front Endocrinol (Lausanne)* 2020; **11**: 530 [PMID: 32849309 DOI: 10.3389/fendo.2020.00530]

64 **Pérez-Campos Mayoral L**, Matias-Cervantes CA, Pérez-Campos E, Romero Díaz C, Laguna Barrios LÁ, Pina Canseco MDS, Martínez Cruz M, Pérez-Campos Mayoral E, Solórzano Mata CJ, Rodal Canales FJ, Martínez Ruíz H, Hernández-Huerta MT. Associations of Dynapenic Obesity and Sarcopenic Obesity with the Risk of Complications in COVID-19. *Int J Mol Sci* 2022; **23** [PMID: 35955411 DOI: 10.3390/ijms23158277]

65 **Sarwar R**, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. *Diabetes Metab Syndr Obes* 2018; **11**: 533-542 [PMID: 30288073 DOI: 10.2147/DMSO.S146339]

66 **Beals JW**, Smith GI, Shankaran M, Fuchs A, Schweitzer GG, Yoshino J, Field T, Matthews M, Nyangau E, Morozov D, Mittendorfer B, Hellerstein MK, Klein S. Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease. *Hepatology* 2021; **74**: 1287-1299 [PMID: 33743554 DOI: 10.1002/hep.31822]

67 **Ter Horst KW**, Gilijamse PW, Versteeg RI, Ackermans MT, Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ. Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. *Cell Rep* 2017; **19**: 1997-2004 [PMID: 28591572 DOI: 10.1016/j.celrep.2017.05.035]

68 **Korenblat KM**, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. *Gastroenterology* 2008; **134**: 1369-1375 [PMID: 18355813 DOI: 10.1053/j.gastro.2008.01.075]

69 **Sanyal AJ**, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001; **120**: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]

70 **Sharpton SR**, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. *Cell Metab* 2021; **33**: 21-32 [PMID: 33296678 DOI: 10.1016/j.cmet.2020.11.010]

71 **Morgan K**, Samuel K, Vandeputte M, Hayes PC, Plevris JN. SARS-CoV-2 Infection and the Liver. *Pathogens* 2020; **9** [PMID: 32486188 DOI: 10.3390/pathogens9060430]

72 **Zhang W**, Li C, Liu B, Wu R, Zou N, Xu YZ, Yang YY, Zhang F, Zhou HM, Wan KQ, Xiao XQ, Zhang X. Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. *Ann Hepatol* 2013; **12**: 892-900 [PMID: 24114819]

73 **Lagana SM**, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. *Mod Pathol* 2020; **33**: 2147-2155 [PMID: 32792598 DOI: 10.1038/s41379-020-00649-x]

74 **Napodano C**, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. *Scand J Immunol* 2021; **93**: e12977 [PMID: 32931622 DOI: 10.1111/sji.12977]

75 **Fara A**, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. *Open Biol* 2020; **10**: 200160 [PMID: 32961074 DOI: 10.1098/rsob.200160]

76 **Pereira SS**, Alvarez-Leite JI. Low-Grade Inflammation, Obesity, and Diabetes. *Curr Obes Rep* 2014; **3**: 422-431 [PMID: 26626919 DOI: 10.1007/s13679-014-0124-9]

77 **Chen VL**, Hawa F, Berinstein JA, Reddy CA, Kassab I, Platt KD, Hsu CY, Steiner CA, Louissaint J, Gunaratnam NT, Sharma P. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. *Dig Dis Sci* 2021; **66**: 3192-3198 [PMID: 32980956 DOI: 10.1007/s10620-020-06618-3]

78 **Elhence A**, Vaishnav M, Biswas S, Anand A, Gunjan D, Kedia S, Mahapatra SJ, Nayak B, Sheikh S, Soni KD, Trikha A, Goel A, Shalimar. Predictors of in-hospital Outcomes in Patients With Cirrhosis and Coronavirus Disease-2019. *J Clin Exp Hepatol* 2022; **12**: 876-886 [PMID: 34728983 DOI: 10.1016/j.jceh.2021.10.014]

**Footnotes**

**Conflict-of-interest statement:** The authors report having no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Athens Medical Association, 072781; European Respiratory Society, 344658

**Peer-review started:** September 12, 2022

**First decision:** December 12, 2022

**Article in press:** January 9, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Hernandez-Caballero A, Mexico; Zhang LL, China **S-Editor:** Wang JJ **L-Editor:** Filipodia **P-Editor:** Wang JJ

**Figure Legends**



**Figure 1 Potential mediators of liver damage associated to coronavirus disease 2019, fatty liver, and obesity.** ACE2: Angiotensin converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2. Parts of the figure were drawn by using pictures from Servier Medical Art (available from: smart.servier.com).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**